OncoMatch/Clinical Trials/NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Is NCT07066657 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including MRG007 and MRG007 and Bevacizumab for locally advanced or metastatic solid tumors.
Treatment: MRG007 · MRG007 and Bevacizumab — This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Gastric Cancer
Pancreatic Cancer
Biomarker criteria
Required: CDH17 any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CDH17-targeting anti-tumor therapy
Received CDH17-targeting anti-tumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- ULCA · Los Angeles, California
- UCSF · San Francisco, California
- University of Colorado · Aurora, Colorado
- Sarah Cannon Research Institute · Denver, Colorado
- Sarah Cannon Research Institute · Sarasota, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07066657 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CDH17-targeting anti-tumor therapy disqualifies patients from enrollment.
Does this trial require CDH17?
Yes, CDH17 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages